Yahoo
Stockholm - Delayed Quote SEK

Apotea AB (publ) (APOTEA.ST)

94.25 +0.25 (+0.27%)
At close: 5:29:35 PM GMT+1
APOTEA.ST Q3 2026 earnings call
November 5, 2026 at 9:30 AM GMT+1
Chart Range Bar
Loading chart for APOTEA.ST
  • Previous Close 94.00
  • Open 93.85
  • Bid 93.95 x --
  • Ask 94.10 x --
  • Day's Range 93.05 - 94.50
  • 52 Week Range 54.42 - 94.50
  • Volume 161,302
  • Avg. Volume 207,311
  • Market Cap (intraday) 9.809B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 39.94
  • EPS (TTM) 2.36
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield 0.60 (0.64%)
  • Ex-Dividend Date May 27, 2026
  • 1y Target Est 92.50

Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, baby, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements. It also provides products in the categories of body care, stomach and intestine, food and drink, mouth and teeth, premium, trip, sex and lust, stop smoking, makeup, sun protection, wounds and injuries, sleep and sleep problems, training, weight control, vitamins and minerals, charity, and eyes and ears. In addition, the company offers leasing and hiring out personnel to related companies, as well as marketing contributions. The company was founded in 2011 and is headquartered in Stockholm, Sweden.

www.apotea.se

736

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

APOTEA.ST
3.00%
OMX Stockholm 30 Index (^OMX)
13.93%

1-Year Return

APOTEA.ST
16.59%
OMX Stockholm 30 Index (^OMX)
19.20%

3-Year Return

APOTEA.ST
22.80%
OMX Stockholm 30 Index (^OMX)
54.43%

5-Year Return

APOTEA.ST
22.80%
OMX Stockholm 30 Index (^OMX)
41.71%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 2.03B
Earnings 81.4M
Profit Margin 4.02%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
500M
1B
2B
2B
0.0%
1.0%
2.0%
3.0%
4.0%

Analyst Insights

View More

Analyst Price Targets

85.00 Low
92.50 Average
94.25 Current
100.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.24%

  • Return on Assets (ttm)

    9.45%

  • Return on Equity (ttm)

    27.83%

  • Revenue (ttm)

    7.59B

  • Net Income Avi to Common (ttm)

    245.7M

  • Diluted EPS (ttm)

    2.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    103.5M

  • Total Debt/Equity (mrq)

    29.01%

  • Levered Free Cash Flow (ttm)

    99.11M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: